A fund launched in 2012 by the biotech venture capital firm Flagship Pioneering is on track to return its investors’ money nine times over.

That’s the eyebrow-raising return multiple for Flagship Ventures Fund IV — the highest recorded return multiple in a new STAT report that took a deep dive into returns data for more than a dozen of the country’s top biotech venture capital firms. The data includes return multiples, like Flagship’s 9x figure, for more than 15 funds, which represent both the value of its existing investments as well as the cash the fund has already returned to investors.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy